

	Targets	Compounds	Developer	Stage of development	ClinicalTrials.gov identifier
Direct acting antivirals	HBpol	GS-7340; Tenofovir Alafenamide Fumarate (prodrug of tenofovir)	Gilead	Approved	NCT01940471 and NCT01940341
	HBpol	AGX-1009 (prodrug of tenofovir)	Agenix/ Cinkate Pharmaceutical	Phase 3	No identifier found
	HBpol	LB80380; Besifovir	IIDong Pharmaceutical	Phase 3	NCT01937806
	HBpol	CMX-157 (prodrug of tenofovir)	Contravir	Phase 2a	NCT02710604
	HBc	GLS-4 (Morphothiadine mesilate)	HEC Pharm/SUNshine	Phase 2	China-CFDA
	HBc	NVR 3-778	Novira Pharmaceuticals/JnJ	Phase 1a	NCT02112799 & NCT02401737
	HBc	JNJ56136379	JnJ Janssen	Phase 1	NCT02662712
	HBc	Core protein Allosteric Modifier (CpAM)	Assembly Biosciences	Phase 1	
	HBs	REP-2139 & 2165 (Nucleic acid polymers)	Replicor	Phase 2 for both HBV and HDV	NCT02565719 and NCT02233075
	Unknown	RG7834	Roche	Phase I	New Zealand
	Viral RNAs	siRNA: ARC-520/ARC-521	Arrowhead	Discontinued	NCT02604212 and NCT02604199
		ALNHBV	Alnylam	Phase 1/2	NCT02826018
	ARB-1467	Arbutus	Phase 2	NCT02631096	
	Lunar HBV	Arcturus /Janssen	Preclinical		
	BB HB 331	Benitec	Preclinical		
Viral RNAs	siRNA: Ionis HBV _{Rx}	Ionis pharmaceuticals/GSK	Phase 1		
	NTCP	Myrcludex	Hepatera	Phase 2 for both HBV and HDV	NCT02881008/NCT02637999
	Promotion of apoptosis in infected cells	Birinapant	Tetralogic	Phase 1	NCT02288208
	Prenylation/farnesylation	Lonafarnib	Eiger BioPharmaceuticals	Phase 2 for HDV	NCT02430181, NCT02430194, NCT02511431
	Immune stimulation	Thymosin alpha	Seoul National	Phase 4	NCT00291616

Host targeting agents	Cyclophilins	CPI431	University Hospital Contravir/ Ciclofilin Pharmaceuticals	preclinical	
	Cyclophilins	NVP018	Neurovive/ OnCore Biopharma	preclinical	
	pDC stimulation	GS-9620 (TLR7 agonist)	Gilead	Phase 2	NCT02579382
	Immune stimulation	INO-1800 (therapeutic vaccine)	Inovio Pharmaceuticals	Phase 1	NCT02431312
	Immune stimulation	Cyt-107 (IL-7)	Cythesis	Phase 1/2 (discontinued)	NCT01027065
	Immune stimulation	SB9200	SpringBank	Phase 2	NCT 02751996
	Immune stimulation	IFN-lambda	BMS	Phase 2 (discontinued)	NCT01204762
	Adaptive responses	ABX-203	Abivax	Phase 2/3	NCT02249988
	Adaptive responses	CVI-HBV-002 (S)	CHA Vaccine Institute	Phase 1/2	NCT02693652
	Adaptive responses	Engerix-B + NA	Chang Gung Memorial Hospital	Phase 4	NCT02505009 NCT01817725
	Adaptive responses	Euvax B (S) + PEG IFN + ETV	Seoul National University	Phase 4	CT02097004
	Adaptive responses	Nivolumab (Anti-PD1 mAb)	Ono Pharmaceuticals/BMS	Phase 1/2 for HCC	NCT01658878
	Adaptive responses	pPDPSC18	Powder Med		NCT00277576
	Adaptive responses	IFN + IL2 + HepB vaccine	Tongji Hospital		NCT02360592
	Adaptive responses	HBsAg-activated MoDC	Sun Yat-Sen University		NCT01935635
	Therapeutic DNA vaccine	HB110	Ichor/Janssen	Phase 1 (completed)	NCT01641536
	Therapeutic vaccine	Tomegavax HBV	TomegaVax	Phase 1	
	Therapeutic vaccine	HepTcell	Altimmune	Phase 1	UK
		FP-02.2 (Peptide vaccine)		Phase 1	NCT02496897
	Therapeutic vaccine	GS-4774	Gilead	Phase 2	NCT02174276
Therapeutic vaccine	TG-1050	Transgene	Phase 1	NCT02428400	
Therapeutic vaccine	DV-601 (S and C)	Dynavax	Phase 1	Completed	
Therapeutic vaccine	HB-110E	Genexine	Phase 1	NCT01641536	
Unknown	RG7795 (ANA773)	Roche	Phase 2		
Unknown	RO6864018	Roche	Phase 2	NCT02391805	

NA: nucleos(t)ide analogue; PEG IFN: pegylated interferon; TLR: toll-like receptor

Supplementary Table 1: List of HBV antiviral and immune modulatory therapies in clinical trials